Page 11 - ஈராஸ்மஸ் பல்கலைக்கழகம் மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
AIM ImmunoTech Inc says subsidiary NV Hemispherx Biopharma Europe receives formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
AIM ImmunoTech Inc : AIM ImmunoTech s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Join ARN
Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.Sign up now
Media releases are provided as is by companies and have not been edited or checked for accuracy. Any queries should be directed to the company itself.
23 February 2021 16:46
Global Next Generation Sequencing Market Is Anticipated To Register Around 14.6% CAGR From 2021-2030
The global Next Generation Sequencing market size was valued at US$ 4.05 billion in 2020 and is anticipated to grow at a CAGR of 14.6% during forecast period 2021 to 2030.
The global Next Generation Sequencing market size is expected to be worth around US$ 11.10 billion by 2030, according to a new report by Vision Research Reports.